We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Outset Medical (OM): Can Its 15.0% Jump Turn into More Strength?
Read MoreHide Full Article
Outset Medical, Inc. (OM - Free Report) shares soared 15% in the last trading session to close at $19.97. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.2% loss over the past four weeks.
Outset Medical recorded a strong price rise on investors’ optimism surrounding the company’s expanding installed base and recurring revenue potential, underpinned by the widespread adoption and utilization of its Tablo dialysis system across acute and home settings. Backed by this momentum, last month, the company reported robust financial results for the first quarter of 2025.
This company is expected to post quarterly loss of $1.76 per share in its upcoming report, which represents a year-over-year change of +75%. Revenues are expected to be $29.77 million, up 8.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Outset Medical, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on OM going forward to see if this recent jump can turn into more strength down the road.
Outset Medical is a member of the Zacks Medical Info Systems industry. One other stock in the same industry, Senseonics Holdings (SENS - Free Report) , finished the last trading session 1.2% higher at $0.5. SENS has returned -1.7% over the past month.
Senseonics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.02. Compared to the company's year-ago EPS, this represents a change of +33.3%. Senseonics currently boasts a Zacks Rank of #2 (Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Outset Medical (OM): Can Its 15.0% Jump Turn into More Strength?
Outset Medical, Inc. (OM - Free Report) shares soared 15% in the last trading session to close at $19.97. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.2% loss over the past four weeks.
Outset Medical recorded a strong price rise on investors’ optimism surrounding the company’s expanding installed base and recurring revenue potential, underpinned by the widespread adoption and utilization of its Tablo dialysis system across acute and home settings. Backed by this momentum, last month, the company reported robust financial results for the first quarter of 2025.
This company is expected to post quarterly loss of $1.76 per share in its upcoming report, which represents a year-over-year change of +75%. Revenues are expected to be $29.77 million, up 8.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Outset Medical, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on OM going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Outset Medical is a member of the Zacks Medical Info Systems industry. One other stock in the same industry, Senseonics Holdings (SENS - Free Report) , finished the last trading session 1.2% higher at $0.5. SENS has returned -1.7% over the past month.
Senseonics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.02. Compared to the company's year-ago EPS, this represents a change of +33.3%. Senseonics currently boasts a Zacks Rank of #2 (Buy).